Clinical trial EMBER-4 - J2J-MC-JZLH
J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Lilly |
| EudraCT Identifier | 2022-501007-28-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05514054 |
| Last update |